Search Results 471-480 of 16933 for Amphotericin B
(B) H&E and IHC for ER showing absence of ER protein in BR-008-e106. Normal breast tissue was used as a positive control. (C) Tumor burden in all treatment ...
This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers. We ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. Testing the Addition of an Anti-cancer ...
Stidham RW, Enchakalody B, Wang SC, Su GL, Ross B, Al-Hawary M, Wasnik AP. Artificial Intelligence for Quantifying Cumulative Small Bowel Disease Severity ...
... B cell maturation antigen (BCMA)-expressing multiple myeloma. bb2121 is defined as autologous T lymphocytes (T cells) transduced ex vivo with anti-BCMA02 ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come ...
... B]. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 SPECT/CT imaging to correctly identify subjects with ...
Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...
Divyanshu (Div) Dubey, M.B.B.S., studies central and peripheral autoimmune neurological conditions. This includes searching for novel biomarkers in serum and ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.